Basal-Bolus the Gold Standard Regimen for Type 1 Diabetes Mellitus (T1DM)

The Embassy of Denmark in Thailand together with Diabetes Association of Thailand and supported by Novo Nordisk Pharma (Thailand) Co., Ltd., a leader in innovative medicines and pharmaceuticals in the treatment of diabetes for more than 99 years, organized a seminar “Basal-Bolus the Gold Standard Regimen for Type 1 Diabetes Mellitus (T1DM)” to promote and drive treatment  for people with diabetes, especially type 1 diabetes, in Thailand at The Athenee Hotel, a Luxury Collection Hotel, Bangkok on Thursday, June 9, 2022. One of the campaigns for World Diabetes Day (World Diabetes Day) that the Diabetes Association of Thailand intends to hold the event continuously for a period of 2 years from November 14, 2021, continuing until 2023. Under the concept of “Together Fight Diabetes Care, If not now, When? “.

The seminar “Basal-Bolus the Gold Standard Regimen for Type 1 Diabetes Mellitus (T1DM)” was organized to promote diabetes care in accordance with the Gold standard regimen used in the care of people with type 1 and type 2 diabetes. Especially in patients with type 1 diabetes who need to receive insulin from birth.  The point of discussion, such as the awareness of the importance of insulin and the need for insulin that physicians currently use in the care of patients with type 1 diabetes, is in line with recommended clinical practice, Basal-Insulin. Is this a bolus regimen? The medical team desire for future care for people with type 1 diabetes. To what extent can new technologies address the challenges of patient care?. Has the cooperation of all organizations from the past to the present succeeded as expected or not? Breaking restrictions to enable patients to access effective care and plans to drive the future so that patients receive the best in all treatment rights

This discussion Honoured by H.E. Mr. Jon Thorgaard, Ambassador of Denmark in Thailand and specialists in diabetes care, led by Prof. Emeritus Wannee Nithiyanant, MD President – Diabetes Association of Thailand, Assoc. Prof. Dr. Petch Rawdaree, Clin. Prof. Dr. Supawadee Likitmaskul, Prof. Taninee Sahakitrungruang, MD. and honoured doctor join to comment on such issues. Mr. John Dawber, Vice President & General Manager of Novo Nordisk Pharma (Thailand) Ltd. revealed that “Novo Nordisk in Founded in 1923 as a leading global healthcare company headquartered in Copenhagen Denmark And having been established in Thailand for over 39 years, we want to drive change and development to overcome diabetes. Supports physicians’ work in administering the basal-bolus regimen, a gold standard regimen, for the treatment of diabetic patients, especially those with type 1 diabetes.”